



## Mucosal Responses in the Context of Natural Immunity to HIV

Guest Editor:

**Dr. Johanne Poudrier**

Département de Microbiologie,  
Infectiologie et Immunologie,  
Université de Montréal, Montréal,  
QC, Canada

Deadline for manuscript  
submissions:

**closed (31 January 2021)**

### Message from the Guest Editor

Dear Colleagues,

Approximately 37 million people are living with HIV/AIDS worldwide. Most HIV infections are acquired through heterosexual intercourse, and in Africa, nearly 60% of new infections affect women. Currently, there is no cure and the development of vaccines and microbicides remains the best solution to eradicate the pandemic. To this end, the development of effective devices will benefit from studies of individuals who are highly-exposed to HIV and yet remain seronegative (HESN) despite several years of exposure. This special issue aims to further our comprehension of the immune responses that govern mucosal ports of entry in individuals presenting natural immunity to HIV. We therefore encourage the presentation of recent advances in this field. Lessons from vaccination trials and passive immunization studies, and those with non-human primates will also be welcome. Understanding the nature and how immune populations are recruited and maintained within mucosal niche to fight HIV is important to the design of effective preventive/therapeutic approaches.

Dr. Johanne Poudrier

*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ger Rijkers

Department of Health, Cognition  
and Behavior, University College  
Roosevelt, 4331 CB Middelburg,  
The Netherlands

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

## Contact Us

---

Vaccines Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)